Combining bioreductive drugs and radiation for the treatment of solid tumors.
Methods now exist for the identification of human tumors that contain significant numbers of hypoxic cells and are thereby suitable for treatment with bioreductive drugs to eliminate this refractory cell population. However, to fully exploit the potential of bioreductive drugs, they will need to be used in combination with other modalities likely to target the proliferating aerobic cells in the tumor. Radiation is the treatment that is most effective in killing aerobic cells; therefore, the present report reviews the available preclinical data on combined radiation/bioreductive drug treatments.
Stratford
Ian J
IJ
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
Williams
Kaye J
KJ
Cowen
Rachel L
RL
Jaffar
Mohammed
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015687:Cell Hypoxia / Q000187:drug effects / Q000528:radiation effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000528:radiation effects; D003131:Combined Modality Therapy / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000503:physiopathology / Q000628:therapy*; D011878:Radiotherapy / Q000639:trends
D000970:Antineoplastic Agents